ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells

Shyamal D. Desai, Ryan E. Reed, Julian Burks, Laurence M. Wood, Ashok K. Pullikuth, Arthur L. Haas, Leroy-Fong Liu, Jerome W. Breslin, Sally Meiners, Surendran Sankar

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The interferon-stimulated gene 15 (ISG15) pathway is highly elevated in breast cancer; however, very little is known about how the ISG15 pathway contributes to breast tumorigenesis. In the current study, using the gene disruption approach, we demonstrate that both ISG15 and UbcH8 (ISG15-specific conjugating enzyme) disrupt F-actin architecture and formation of focal adhesions in ZR-75-1 breast cancer cells. In addition, ISG15 and UbcH8 promote breast cancer cell migration. We also demonstrate that ISG15 inhibits ubiquitin/26S proteasome-mediated turnover of proteins implicated in tumor cell motility, invasion and metastasis. Together, our results suggest that the aberrant activation of the ISG15 pathway confers a motile phenotype to breast cancer cells by disrupting cell architecture and stabilizing proteins involved in cell motility, invasion and metastasis. Because the cellular architecture is conserved and the ISG15 pathway is constitutively activated in tumor cells of different lineages, it is reasonable to assume that our observations in breast cancer must hold true for many other tumors.

Original languageEnglish
Pages (from-to)38-49
Number of pages12
JournalExperimental Biology and Medicine
Volume237
Issue number1
DOIs
Publication statusPublished - Jan 2012
Externally publishedYes

Fingerprint

Interferons
Genes
Cells
Breast Neoplasms
Cell Movement
Tumors
Neoplasm Metastasis
Neoplasms
Focal Adhesions
Cell Lineage
Ubiquitin
Actins
Carcinogenesis
Proteins
Breast
Adhesion
Chemical activation
Phenotype
Enzymes

Keywords

  • Breast cancer
  • Cell architecture
  • Cell migration
  • Interferon
  • ISG15
  • Ubiquitin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Desai, S. D., Reed, R. E., Burks, J., Wood, L. M., Pullikuth, A. K., Haas, A. L., ... Sankar, S. (2012). ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Experimental Biology and Medicine, 237(1), 38-49. https://doi.org/10.1258/ebm.2011.011236

ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. / Desai, Shyamal D.; Reed, Ryan E.; Burks, Julian; Wood, Laurence M.; Pullikuth, Ashok K.; Haas, Arthur L.; Liu, Leroy-Fong; Breslin, Jerome W.; Meiners, Sally; Sankar, Surendran.

In: Experimental Biology and Medicine, Vol. 237, No. 1, 01.2012, p. 38-49.

Research output: Contribution to journalArticle

Desai, SD, Reed, RE, Burks, J, Wood, LM, Pullikuth, AK, Haas, AL, Liu, L-F, Breslin, JW, Meiners, S & Sankar, S 2012, 'ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells', Experimental Biology and Medicine, vol. 237, no. 1, pp. 38-49. https://doi.org/10.1258/ebm.2011.011236
Desai, Shyamal D. ; Reed, Ryan E. ; Burks, Julian ; Wood, Laurence M. ; Pullikuth, Ashok K. ; Haas, Arthur L. ; Liu, Leroy-Fong ; Breslin, Jerome W. ; Meiners, Sally ; Sankar, Surendran. / ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. In: Experimental Biology and Medicine. 2012 ; Vol. 237, No. 1. pp. 38-49.
@article{ce7e1536d479468ebdbd49af230ebf26,
title = "ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells",
abstract = "The interferon-stimulated gene 15 (ISG15) pathway is highly elevated in breast cancer; however, very little is known about how the ISG15 pathway contributes to breast tumorigenesis. In the current study, using the gene disruption approach, we demonstrate that both ISG15 and UbcH8 (ISG15-specific conjugating enzyme) disrupt F-actin architecture and formation of focal adhesions in ZR-75-1 breast cancer cells. In addition, ISG15 and UbcH8 promote breast cancer cell migration. We also demonstrate that ISG15 inhibits ubiquitin/26S proteasome-mediated turnover of proteins implicated in tumor cell motility, invasion and metastasis. Together, our results suggest that the aberrant activation of the ISG15 pathway confers a motile phenotype to breast cancer cells by disrupting cell architecture and stabilizing proteins involved in cell motility, invasion and metastasis. Because the cellular architecture is conserved and the ISG15 pathway is constitutively activated in tumor cells of different lineages, it is reasonable to assume that our observations in breast cancer must hold true for many other tumors.",
keywords = "Breast cancer, Cell architecture, Cell migration, Interferon, ISG15, Ubiquitin",
author = "Desai, {Shyamal D.} and Reed, {Ryan E.} and Julian Burks and Wood, {Laurence M.} and Pullikuth, {Ashok K.} and Haas, {Arthur L.} and Leroy-Fong Liu and Breslin, {Jerome W.} and Sally Meiners and Surendran Sankar",
year = "2012",
month = "1",
doi = "10.1258/ebm.2011.011236",
language = "English",
volume = "237",
pages = "38--49",
journal = "Experimental Biology and Medicine",
issn = "1535-3702",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells

AU - Desai, Shyamal D.

AU - Reed, Ryan E.

AU - Burks, Julian

AU - Wood, Laurence M.

AU - Pullikuth, Ashok K.

AU - Haas, Arthur L.

AU - Liu, Leroy-Fong

AU - Breslin, Jerome W.

AU - Meiners, Sally

AU - Sankar, Surendran

PY - 2012/1

Y1 - 2012/1

N2 - The interferon-stimulated gene 15 (ISG15) pathway is highly elevated in breast cancer; however, very little is known about how the ISG15 pathway contributes to breast tumorigenesis. In the current study, using the gene disruption approach, we demonstrate that both ISG15 and UbcH8 (ISG15-specific conjugating enzyme) disrupt F-actin architecture and formation of focal adhesions in ZR-75-1 breast cancer cells. In addition, ISG15 and UbcH8 promote breast cancer cell migration. We also demonstrate that ISG15 inhibits ubiquitin/26S proteasome-mediated turnover of proteins implicated in tumor cell motility, invasion and metastasis. Together, our results suggest that the aberrant activation of the ISG15 pathway confers a motile phenotype to breast cancer cells by disrupting cell architecture and stabilizing proteins involved in cell motility, invasion and metastasis. Because the cellular architecture is conserved and the ISG15 pathway is constitutively activated in tumor cells of different lineages, it is reasonable to assume that our observations in breast cancer must hold true for many other tumors.

AB - The interferon-stimulated gene 15 (ISG15) pathway is highly elevated in breast cancer; however, very little is known about how the ISG15 pathway contributes to breast tumorigenesis. In the current study, using the gene disruption approach, we demonstrate that both ISG15 and UbcH8 (ISG15-specific conjugating enzyme) disrupt F-actin architecture and formation of focal adhesions in ZR-75-1 breast cancer cells. In addition, ISG15 and UbcH8 promote breast cancer cell migration. We also demonstrate that ISG15 inhibits ubiquitin/26S proteasome-mediated turnover of proteins implicated in tumor cell motility, invasion and metastasis. Together, our results suggest that the aberrant activation of the ISG15 pathway confers a motile phenotype to breast cancer cells by disrupting cell architecture and stabilizing proteins involved in cell motility, invasion and metastasis. Because the cellular architecture is conserved and the ISG15 pathway is constitutively activated in tumor cells of different lineages, it is reasonable to assume that our observations in breast cancer must hold true for many other tumors.

KW - Breast cancer

KW - Cell architecture

KW - Cell migration

KW - Interferon

KW - ISG15

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=84862939684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862939684&partnerID=8YFLogxK

U2 - 10.1258/ebm.2011.011236

DO - 10.1258/ebm.2011.011236

M3 - Article

VL - 237

SP - 38

EP - 49

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 1535-3702

IS - 1

ER -